uniQure Proposes $150M Offering of Shares and Warrants to Fund AMT-130 Commercialization

summarizeSummary

uniQure N.V. announced a $150 million public offering of ordinary shares and pre-funded warrants to fund the commercialization and development of its lead gene therapy candidate, AMT-130, and other programs.

check_boxKey Events

• Proposed $150 Million Offering

  uniQure N.V. is proposing a public offering of $150 million in ordinary shares and pre-funded warrants, as detailed in this preliminary prospectus supplement.

• Strategic Use of Proceeds

  The net proceeds are intended to fund commercialization readiness, potential launches, and a confirmatory study for its lead Huntington's disease candidate, AMT-130, along with other clinical development and general corporate purposes.

• Significant Dilution Expected

  The offering, which includes pre-funded warrants with a nominal exercise price, is expected to cause immediate and substantial dilution for existing shareholders.

• Follows Positive Regulatory News

  This capital raise follows recent positive FDA feedback on June 17, 2026, indicating that 3-year Phase I/II study data for AMT-130 would be acceptable as the primary basis for a Biologics License Application (BLA) submission in Q3 2026.

auto_awesomeAnalysis

uniQure N.V. is launching a substantial $150 million public offering of ordinary shares and pre-funded warrants. This capital raise, representing approximately 5.4% of the company's market capitalization, is strategically timed following recent positive FDA feedback for its lead Huntington's disease candidate, AMT-130. The proceeds are earmarked for critical commercialization readiness activities, potential launches, and a confirmatory study for AMT-130, as well as other clinical development and general corporate purposes. While the offering will result in immediate and substantial dilution for existing shareholders, it provides essential funding to advance the company's key therapeutic programs towards market.